# A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

> **NCT00781443** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** lebrikizumab (MILR1444A)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00781443
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-11
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2010-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781443, "A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00781443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*